Company Filing History:
Years Active: 2019
Title: David Raymond Plowchalk: Innovator in Therapeutic Dosing Regimens
Introduction
David Raymond Plowchalk is a notable inventor based in Waterford, CT (US). He has made significant contributions to the field of medicine, particularly in the development of therapeutic strategies for managing cholesterol levels.
Latest Patents
Plowchalk holds a patent for "Treatment with anti-PCSK9 antibodies." This invention relates to therapeutic dosing regimens that utilize a dose reduction strategy for treating disorders characterized by marked elevations of low-density lipoprotein cholesterol (LDL-C) in the plasma of a patient. The therapeutic dosing regimens involve delivering an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody as an initial dose of at least about 100 mg. Subsequent doses may be administered in amounts that are about the same as the initial dose or at least half the initial dose after the patient achieves an LDL-C level at or below about 10 mg/dL.
Career Highlights
Plowchalk is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work focuses on innovative approaches to cholesterol management, contributing to advancements in cardiovascular health.
Collaborations
Plowchalk collaborates with Anne Barbara Cropp, enhancing the research and development efforts within his field.
Conclusion
David Raymond Plowchalk's contributions to therapeutic dosing regimens exemplify the impact of innovation in medicine. His work continues to influence the treatment of cholesterol-related disorders, showcasing the importance of research and development in healthcare.